News from Acacia Pharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

13 Feb, 2017, 03:00 ET Acacia Pharma Announces Positive Results From its Fourth and Final Pivotal Trial of BAREMSIS™ for the Rescue Treatment of PONV

Extensive Phase 3 programme demonstrates clinical potential of BAREMSIS in rescue treatment and prophylaxis of PONV - NDA to be submitted to the...


12 Aug, 2016, 03:00 ET Acacia Pharma Announces Positive Results From a Pivotal Phase 3 Trial of BAREMSIS™ for the Treatment of Post-Operative Nausea & Vomiting

BAREMSIS Now Shown to Treat PONV, as Well as Prevent it  Acacia Pharma Group plc ("Acacia Pharma"), the supportive care company developing...


21 Mar, 2016, 04:00 ET Acacia Pharma Initiates Second Pivotal Phase 3 Treatment Study with Baremsis™ (APD421) in Post-Operative Nausea & Vomiting (PONV)

NDA filing expected in second half of 2016  Acacia Pharma Group plc ("Acacia Pharma"), the supportive care company developing products for...


05 Jan, 2016, 03:00 ET Acacia Pharma Announces Positive Results from Second Pivotal Phase 3 Study of BAREMSIS™ (APD421) in Prevention of Post-operative Nausea & Vomiting

Acacia Pharma Group plc ("Acacia Pharma"), the supportive care company developing products for US and international markets, announces positive...


03 Dec, 2015, 04:00 ET Acacia Pharma: Dr Patrick Vink to Succeed Ian Kent as Non-Executive Chairman

Acacia Pharma Group plc ("Acacia Pharma"), the supportive care company developing products for US and international markets, today announces that...


07 Oct, 2014, 03:00 ET Acacia Pharma Announces Positive Phase 3 Results For APD421 in Post-Operative Nausea & Vomiting (PONV)

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated...


30 Oct, 2013, 04:00 ET Acacia Pharma Initiates Phase II Study With APD403 in Chemotherapy Induced Nausea & Vomiting (CINV)

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study...


15 Oct, 2013, 03:00 ET Acacia Pharma Announces Positive Phase II Results With APD515 for Xerostomia in Advanced Cancer

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces positive results from its Phase II...


17 Sep, 2013, 03:00 ET Acacia Pharma Initiates Pivotal Phase 3 Studies with APD421 in Post-Operative Nausea & Vomiting (PONV)

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of two pivotal...


03 Sep, 2013, 03:00 ET Acacia Pharma Raises £15 Million ($23.5 Million) to Advance Clinical Development of Lead Products for Supportive Care

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised £15 million...


28 May, 2012, 06:30 ET Acacia Pharma Announces Excellent Phase II Results for APD421 in Post-Operative Nausea & Vomiting (PONV)

Acacia Pharma announces positive results from its Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). The...


31 Mar, 2011, 09:00 ET Acacia Pharma Closes $10 Million Investment Round

- Funds to be Used to Complete Two Phase II Programmes Acacia Pharma, a pharmaceutical company specialising in the development of drugs for...